AnaptysBio Inc logo

ANAB - AnaptysBio Inc News Story

$24.51 -1.4  -5.4%

Last Trade - 18/05/21

Mid Cap
Market Cap £501.9m
Enterprise Value £232.8m
Revenue £50.4m
Position in Universe 3190th / 6846

BUZZ-AnaptysBio: Analysts disappointed after drug fails late-stage study

Tue 9th March, 2021 2:05pm
** At least two brokerages downgrade drug developer  ANAB.O 
after co's skin disorder drug fails to meet the primary goal in
a late-stage study 
    ** Co said on Monday its imsidolimab treatment, meant to
lower the severity of skin disorder palmoplantar pustulosis
(PPP), did not show statistically significant improvement over
    ** J.P.Morgan downgrades co to "underweight" from
"overweight", cuts PT to $17 from $40 
    ** "This is certainly a disappointing outcome and is another
high-profile clinical setback for co," says JPM 
    ** JPM now views co as an underperformer in comparison to
the broader biotech group, driven by negative sentiment
    ** Wedbush also downgrades ANAB to "neutral" from
"outperform", cuts PT to $19 from $35
    ** Says though co has enough cash to provide operational
runway into 2024, there is lack of near-term catalysts
    ** Shares down 1.2% at $19.28 premarket after falling over
33% on Monday
    ** ANAB down over 9% YTD, as of last close

 (Reporting by Tapanjana Rudra)
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.